Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2322364
Max Phase: Preclinical
Molecular Formula: C30H30N6O
Molecular Weight: 490.61
Molecule Type: Small molecule
Associated Items:
ID: ALA2322364
Max Phase: Preclinical
Molecular Formula: C30H30N6O
Molecular Weight: 490.61
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1cc(C)c(-c2nc3nc(N4CCC4)ccc3[nH]2)cc1C(=O)N1CCC(c2ccc(C#N)cc2)CC1
Standard InChI: InChI=1S/C30H30N6O/c1-19-16-20(2)25(30(37)36-14-10-23(11-15-36)22-6-4-21(18-31)5-7-22)17-24(19)28-32-26-8-9-27(33-29(26)34-28)35-12-3-13-35/h4-9,16-17,23H,3,10-15H2,1-2H3,(H,32,33,34)
Standard InChI Key: DJIVQMKWCXHKBI-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 490.61 | Molecular Weight (Monoisotopic): 490.2481 | AlogP: 5.34 | #Rotatable Bonds: 4 |
Polar Surface Area: 88.91 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 11.31 | CX Basic pKa: 2.87 | CX LogP: 5.43 | CX LogD: 5.43 |
Aromatic Rings: 4 | Heavy Atoms: 37 | QED Weighted: 0.42 | Np Likeness Score: -1.51 |
1. Oslob JD, Johnson RJ, Cai H, Feng SQ, Hu L, Kosaka Y, Lai J, Sivaraja M, Tep S, Yang H, Zaharia CA, Evanchik MJ, McDowell RS.. (2013) Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation., 4 (1): [PMID:24900571] [10.1021/ml300335r] |
2. (2014) Heterocyclic modulators of lipid synthesis, |
Source(2):